Celltrion to release Stelara biosimilar in US from March 2025

S.Korean pharmaceutical company finalizes patent agreement for CT-P43 biosimilar in US with Johnson & Johnson

Celltrion to release Stelara biosimilar in US from March 2025
Ji-Hyun Lee 1
2023-08-25 15:14:33 bluesky@hankyung.com
Bio & Pharma

South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it has completed a patent agreement with Johnson & Johnson, the multinational pharmaceutical company that owns Janssen, in relation to the biosimilar drug Stelara (active ingredient: Ustekinumab) used for autoimmune diseases within the US. 

As a result of this agreement, Celltrion's Stelara biosimilar, known as CT-P43, will be able to enter the market starting from March 7, 2025, following its approval in the US.

The company submitted an application for approval to the US Food and Drug Administration (FDA) in June of this year, with the goal of obtaining product approval next year.

Stelara is a therapeutic agent developed by Janssen for autoimmune diseases such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. The substance patents for Stelara are set to expire in the US in September this year and in Europe in July next year.

Considering that Celltrion already has Remsima entering the US market, the introduction of CT-P43 is expected to strengthen its competitive position.

Write to Ji-Hyun Lee at bluesky@hankyung.com

Celltrion considers listing holding firm after merger of 3 units

Celltrion considers listing holding firm after merger of 3 units

Celltrion Group founder and Chairman Seo Jung-jin South Korean drug giant Celltrion Group will consider listing its holding company if necessary, after it completes the merger of three affiliates – biopharmaceutical developer Celltrion Inc., overseas sales and marketing firm Celltrion Hea

Celltrion’s Vegzelma listed on prescription of 10 private US insurers

Celltrion’s Vegzelma listed on prescription of 10 private US insurers

South Korea’s Celltrion Healthcare Co. announced on Wednesday that it has signed contracts with 10 insurance providers in the US to boost the prescription of Vegzelma (active ingredient: bevacizumab), a biosimilar to the anti-cancer drug Avastin. This move could make the drug access

Celltrion gets OK partial approval for phase 3 of biosimilar in Europe

Celltrion gets OK partial approval for phase 3 of biosimilar in Europe

South Korean biopharmaceutical company Celltrion Inc. announced on Tuesday that it has received approval from the European Medicines Agency (EMA) for Part 1 of the phase 3 clinical trial plan of the Ocrevus biosimilar CT-P53.In this phase 3 trial, Celltrion will conduct comparative studies of

Celltrion to merge with global sales affiliate by end-2023

Celltrion to merge with global sales affiliate by end-2023

Celltrion Group founder and Chairman Seo Jung-jin speaks at an online platform press conference on Aug. 17  South Korean pharmaceutical giant Celltrion Group has begun procedures to merge biopharmaceuticals developer and producer Celltrion Inc. with Celltrion Healthcare Co., which focuses

Celltrion applies for approval in US for eye treatment biosimilar

Celltrion applies for approval in US for eye treatment biosimilar

South Korean biopharmaceutical company Celltrion Inc. on Friday said it applied for approval from the US Food and Drug Administration (FDA) for CT-P42, a biosimilar of the eye treatment Eylea.Based on the results of Phase 3 clinical trials worldwide of CT-P42, Celltrion applied with the FDA fo

(* comment hide *}